Evidence map›Paper›PMID 38978104›Full record

ArticleTropical medicine and health2024

Addressing bottlenecks in Lassa fever treatment: overcoming the ribavirin parenteral formulation challenge.

Qudus Olajide Lawal, Joseph Okoeguale, Sebastine Oseghae Oiwoh, ThankGod Akhigbe, Reuben Agbons Eifediyi, Sylvanus Akhalufo Okogbenin

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Tropical medicine and health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qudus Olajide LawalDepartment of Obstetrics and Gynaecology, Irrua Specialist Teaching Hospital, Irrua, 310114, Edo State, Nigeria. lawalqduso@gmail.com.ORCID http://orcid.org/0000-0002-8951-7705
Joseph OkoegualeDepartment of Obstetrics and Gynaecology, Irrua Specialist Teaching Hospital, Irrua, 310114, Edo State, Nigeria.
Sebastine Oseghae OiwohDepartment of Internal Medicine, Irrua Specialist Teaching Hospital, Irrua, 310114, Edo State, Nigeria.
ThankGod AkhigbeDepartment of Internal Medicine, Irrua Specialist Teaching Hospital, Irrua, 310114, Edo State, Nigeria.
Reuben Agbons EifediyiDepartment of Obstetrics and Gynaecology, Irrua Specialist Teaching Hospital, Irrua, 310114, Edo State, Nigeria.
Sylvanus Akhalufo OkogbeninDepartment of Obstetrics and Gynaecology, Irrua Specialist Teaching Hospital, Irrua, 310114, Edo State, Nigeria.

Funding

Expanding cancer research capacity in Nigeria with team scienceD43CA260646 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI T PETER KINGHAM · 2022 to 2026
$1.4M
NCI NIH HHS D43 CA260646
6 · The paper itself

Abstract

Ribavirin ampoule formulation remains a major challenge in managing Lassa fever disease. Lassa fever is an endemic viral hemorrhagic fever in the West Africa subregion, which has high-dose ribavirin as the standard of care. The high-dose therapy required makes the 200 mg/ml ampoule dosing of ribavirin a daunting task to administer, especially during disease outbreaks. This commentary highlights the challenges and makes a passionate call for vial dosage adjustment to fit the high-dose requirement of Lassa fever disease.

Indexed as

AmpouleAntiviral therapyDose formulationLassa feverRibavirin

Identifiers

PMID38978104
PMCPMC11229249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.